<DOC>
	<DOCNO>NCT02503657</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind , 6-month study follow 6 month open-label extension phase evaluate efficacy , safety , tolerability MN-001 moderate severe IPF patient . MN-001 750 mg match placebo orally administer twice daily 26 week period subject confirm diagnosis IPF per ATS ) American Thoracic Society ) 2011 Guidelines . Approximately 15 subject plan enrol . This study consist two treatment arm , MN-001 match placebo . Randomization occur 2:1 ratio ( MN-001 : placebo ) . Eligible subject consist male female range age 21 80 year old , inclusive . The study consist Screening Phase ( 3 month prior Day1 ) follow 26 week double-blind Treatment Phase , 26 week Open-Label Extension ( OLE ) phase Follow-up Visit ( within 4 week last dose ) .</brief_summary>
	<brief_title>Safety Tolerability Study Subjects With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male female subject age 21 80 , inclusive Presence IPF confirm per ATS criterion ( 2011 ) Presence moderate severe disease , stage IIIII define GAP index ( Gender , Age Physiology ) Subjects currently treat OFEV™/Nintedanib stable dose least 3 month prior initiation study drug . Females childbearing potential must negative serum ßhCG ( human chorionic gonadotropin ) screening must willing use appropriate contraception ( defined investigator ) duration study treatment 30 day last dose study treatment . Males practice contraception duration study treatment 30 day last dose study treatment follow : condom use contraception female partner . Subject stable condition basis medical history , physical examination , laboratory screening , determine investigator . Subject willing able comply protocol assessment visit , opinion study nurse/coordinator Investigator . Written inform consent obtain prior participate study . Expected receive lung transplant within 1 year start Treatment Phase lung transplant wait list start Treatment Phase . Known explanation interstitial lung disease Subjects OFEV™/Nintedanib dose interruption due significant adverse event within 6 week screen visit . Ongoing IPF treatment investigational therapy Ongoing IPF treatment Esbriet® ( Pirfenidone ) Immunosuppressants ( i.e. , Mycophenolate , Imuran , Cyclophosphamide ) , cytokine modulating agent within 1 month Screening Visit throughout study Use antibiotic systemic steroid due IPF exacerbation within 1 month Screening Visit Clinically significant cardiovascular disease , include myocardial infarct within last 6 month , unstable ischemic heart disease , congestive heart failure angina Resting pulse &lt; 50 bpm , SA ( sinoatrial ) AV ( atrioventricular ) block , uncontrolled hypertension , QTcF ( QT interval correct use Fridericia formula ) &gt; 450 m Immune system disease Any significant laboratory abnormality , opinion Investigator , may put subject risk History malignancy &lt; 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . History evidence drug alcohol abuse History HIV ( human immunodeficiency virus ) active infection . Currently clinically significant medical condition include follow : neurological , psychiatric , immunological , metabolic , hepatic , hematological , pulmonary ( IPF ) , cardiovascular ( include uncontrolled hypertension ) , gastrointestinal , urological disorder , central nervous system ( CNS ) infection would pose risk subject participate study might confound result study . Note : Active medical condition minor wellcontrolled exclusionary , judgment Investigator , affect risk subject study result . In case impact condition upon risk subject study result unclear , Medical Monitor consult . CYP2C8 ( cytochrome P450 isoenzyme C28 ) CYP2C9 ( cytochrome P450 isoenzyme C29 ) substrates narrow therapeutic index ( i.e . paclitaxel , phenytoin Swarfarin ) within 14 day Screening Visit throughout study . Beta blocker within 14 day Screening Visit throughout study Macrolide quinolone class antibiotic within 14 day Screening Visit throughout study . Poor peripheral venous access limit ability draw blood judge Investigator . Currently participate , participate , study investigational market compound device within 3 month prior sign inform consent . Unwilling unable conduct Spirometry ( Vital Capacity ) test . Unable cooperate study procedure , unlikely adhere study procedure keep appointment , opinion Investigator , plan relocate study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>tipelukast</keyword>
	<keyword>IPF</keyword>
	<keyword>fibrosis</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
</DOC>